Pfizer Expands Access to HIV Rx Maraviroc As Monogram Tests for CCR5-Tropism

Pfizer will make available its investigational HIV drug Maraviroc to patients with limited treatment options due to drug resistance or intolerance to therapy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.